These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 3401258)
1. The carboxylic ionophore monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells. Sehested M; Skovsgaard T; Roed H Biochem Pharmacol; 1988 Sep; 37(17):3305-10. PubMed ID: 3401258 [TBL] [Abstract][Full Text] [Related]
2. Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells. Sehested M; Bindslev N; Demant EJ; Skovsgaard T; Jensen PB Biochem Pharmacol; 1989 Sep; 38(18):3017-27. PubMed ID: 2571333 [TBL] [Abstract][Full Text] [Related]
3. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein. Nielsen D; Maare C; Skovsgaard T Biochem Pharmacol; 1994 Jun; 47(12):2125-35. PubMed ID: 7913318 [TBL] [Abstract][Full Text] [Related]
4. Cytosolic free Ca2+ in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca2+ changes. Bouchelouche P; Friche E; Sehested M; Jensen PB; Skovsgaard T Biochem Pharmacol; 1991 Jan; 41(2):243-53. PubMed ID: 1899193 [TBL] [Abstract][Full Text] [Related]
5. Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells. Sehested M; Skovsgaard T; Jensen PB; Demant EJ; Friche E; Bindslev N Br J Cancer; 1990 Jul; 62(1):37-41. PubMed ID: 1975202 [TBL] [Abstract][Full Text] [Related]
6. A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug-resistant tumor cells. Demant EJ; Sehested M; Jensen PB Biochim Biophys Acta; 1990 Nov; 1055(2):117-25. PubMed ID: 2242381 [TBL] [Abstract][Full Text] [Related]
7. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Friche E; Jensen PB; Sehested M; Demant EJ; Nissen NN Cancer Commun; 1990; 2(9):297-303. PubMed ID: 1976341 [TBL] [Abstract][Full Text] [Related]
8. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide. Nielsen D; Maare C; Eriksen J; Litman T; Friche E; Skovsgaard T Biochem Pharmacol; 2000 Aug; 60(3):353-61. PubMed ID: 10856430 [TBL] [Abstract][Full Text] [Related]
9. Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil. Nielsen D; Maare C; Skovsgaard T Biochem Pharmacol; 1995 Aug; 50(4):443-50. PubMed ID: 7646548 [TBL] [Abstract][Full Text] [Related]
10. Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells. Nielsen D; Eriksen J; Maare C; Friche E; Skovsgaard T Cancer Chemother Pharmacol; 2002 Jun; 49(6):453-60. PubMed ID: 12107549 [TBL] [Abstract][Full Text] [Related]
11. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Friche E; Jensen PB; Nissen NI Cancer Chemother Pharmacol; 1992; 30(3):235-7. PubMed ID: 1628375 [TBL] [Abstract][Full Text] [Related]
12. Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation. Nielsen D; Maare C; Eriksen J; Litman T; Skovsgaard T Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1050-7. PubMed ID: 11704330 [TBL] [Abstract][Full Text] [Related]
13. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells. Friche E; Demant EJ; Sehested M; Nissen NI Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288 [TBL] [Abstract][Full Text] [Related]
14. Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo. Friche E; Danks MK; Beck WT Cancer Res; 1992 Oct; 52(20):5701-6. PubMed ID: 1356619 [TBL] [Abstract][Full Text] [Related]
15. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Friche E; Danks MK; Schmidt CA; Beck WT Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312 [TBL] [Abstract][Full Text] [Related]
16. Relationship of VP-16 to the classical multidrug resistance phenotype. Sehested M; Friche E; Jensen PB; Demant EJ Cancer Res; 1992 May; 52(10):2874-9. PubMed ID: 1581902 [TBL] [Abstract][Full Text] [Related]
17. In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues. Friche E; Jensen PB; Roed H; Skovsgaard T; Nissen NI Biochem Pharmacol; 1990 Jun; 39(11):1721-6. PubMed ID: 2344368 [TBL] [Abstract][Full Text] [Related]
18. Monensin and verapamil do not alter intracellular localisation of daunorubicin in multidrug resistant human KB cells. Wood DJ; Rumsby MG; Warr JR Cancer Lett; 1996 Nov; 108(1):41-7. PubMed ID: 8950207 [TBL] [Abstract][Full Text] [Related]